Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy – FierceBiotech
|
Sanofi drops Voyager’s phase 2/3 Parkinson’s gene therapy
FierceBiotech Sanofi has walked away from the Parkinson’s gene therapy covered by its $845 million alliance with Voyager Therapeutics. The decision gives Voyager the full global rights to VY-AADC but leaves it without a partner as it gears up for a pivotal global … |
Finance Wire |
Global Synthetic Biology Market Size will Exceed US$ 38 Billion By …
Finance Wire The synthetic biology market is expected to exceed more than US$38 billion by 2020. Synthetic Biology Market Promise CAGR of 32.60% During 2013 to …Medgadget (blog) Prof George Church joins Nuclera’s Scientific Advisory Board …Cambridge Network |
Finance Wire |
Global Synthetic Biology Market Size will Exceed US$ 38 Billion By …
Finance Wire The synthetic biology market is expected to exceed more than US$38 billion by 2020. Synthetic Biology Market Promise CAGR of 32.60% During 2013 to …Medgadget (blog) Prof George Church joins Nuclera’s Scientific Advisory Board …Cambridge Network |
|
Genzyme Opts Out of Voyager Gene Therapy for Parkinson’s Disease
Genetic Engineering & Biotechnology News Voyager insisted that the decision did not signal an end to the companies’ up-to-$845 million collaboration, launched in 2015. Voyager and Genzyme agreed to develop and commercialize new adeno-associated virus (AAV) gene therapies for CNS disorders. |
pharmaphorum |
Novartis files CAR–T in lymphoma, sets up rivalry with Gilead
pharmaphorum The new US filing announced today means Novartis is pursuing approval in relapsed/refractory diffuse large B-cell (r/r DLBCL) lymphoma patients ineligible for autologous stem cell transplant. Kymriah was the first CAR–T drug to gain US approval in … Novartis asks FDA to expand Kymriah’s use against blood cancerNasdaq Novartis submits application to FDA for KymriahTM (tisagenlecleucel …GlobeNewswire (press release) Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCLMarkets Insider PMLiVE –The Pharma Letter all 16 news articles » |
Nasdaq |
Novartis asks FDA to expand Kymriah’s use against blood cancer
Nasdaq With CAR–T therapies, patients’ immune cells are taken from their bodies, genetically re-engineered to fight their cancer and then reinfused. Novartis has set the price for Kymriah at $475,000 for young patients with ALL, but the Basel-based company … Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking …GlobeNewswire (press release) |